GlassScriptPhysician profile
Debora L Ferguson
NPI 1902812100
$11,518.08
in general payments reported to CMS, 2019-2025
22 companies · $2,330 in 2025
The $2,330 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,787 · 2020: $1,045 · 2021: $1,486 · 2022: $1,112 · 2023: $1,143 · 2024: $1,615 · 2025: $2,330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,088.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $3,274.36 | 2019-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $2,191.74 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $1,738.51 | 2019-2025 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $1,112.77 | 2019-2025 | Trintellix |
| Corium, LLC | $738.59 | 2023-2025 | Azstarys |
| Alkermes, INC. | $599.24 | 2023-2025 | Lybalvi, Aristada |
| Axsome Therapeutics, INC. | $290.28 | 2023-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $267.76 | 2024-2025 | Qelbree |
| Shire North American Group INC | $230.98 | 2019 | |
| Ironshore Pharmaceuticals INC. | $223.10 | 2019-2024 | |
| Vanda Pharmaceuticals INC. | $167.49 | 2019 | |
| Neuronetics, INC. | $120.21 | 2019 | |
| Lilly USA, LLC | $99.99 | 2025 | Kisunla |
| Tris Pharma INC | $84.84 | 2019-2025 | Dyanavel Xr |
| Arbor Pharmaceuticals, INC. | $73.43 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $66.68 | 2019-2025 | Relexxii |
| Janssen Pharmaceuticals, INC | $55.19 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $53.58 | 2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $46.52 | 2025 | Quviviq |
| Owp Pharmaceuticals, INC. | $30.44 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $26.59 | 2022 | |
| Neos Therapeutics, LP | $25.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debora Ferguson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.